1. Home
  2. GKOS vs ALKS Comparison

GKOS vs ALKS Comparison

Compare GKOS & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • ALKS
  • Stock Information
  • Founded
  • GKOS 1998
  • ALKS 1987
  • Country
  • GKOS United States
  • ALKS Ireland
  • Employees
  • GKOS N/A
  • ALKS 1800
  • Industry
  • GKOS Medical/Dental Instruments
  • ALKS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GKOS Health Care
  • ALKS Health Care
  • Exchange
  • GKOS Nasdaq
  • ALKS Nasdaq
  • Market Cap
  • GKOS 5.4B
  • ALKS 5.0B
  • IPO Year
  • GKOS 2015
  • ALKS 1991
  • Fundamental
  • Price
  • GKOS $87.64
  • ALKS $30.26
  • Analyst Decision
  • GKOS Strong Buy
  • ALKS Strong Buy
  • Analyst Count
  • GKOS 13
  • ALKS 14
  • Target Price
  • GKOS $120.38
  • ALKS $41.43
  • AVG Volume (30 Days)
  • GKOS 718.5K
  • ALKS 1.8M
  • Earning Date
  • GKOS 10-29-2025
  • ALKS 10-28-2025
  • Dividend Yield
  • GKOS N/A
  • ALKS N/A
  • EPS Growth
  • GKOS N/A
  • ALKS 21.99
  • EPS
  • GKOS N/A
  • ALKS 2.08
  • Revenue
  • GKOS $432,953,000.00
  • ALKS $1,505,296,000.00
  • Revenue This Year
  • GKOS $28.90
  • ALKS N/A
  • Revenue Next Year
  • GKOS $25.57
  • ALKS $1.59
  • P/E Ratio
  • GKOS N/A
  • ALKS $14.58
  • Revenue Growth
  • GKOS 26.70
  • ALKS N/A
  • 52 Week Low
  • GKOS $77.10
  • ALKS $25.17
  • 52 Week High
  • GKOS $163.71
  • ALKS $36.45
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 53.74
  • ALKS 51.12
  • Support Level
  • GKOS $82.19
  • ALKS $30.77
  • Resistance Level
  • GKOS $86.74
  • ALKS $32.40
  • Average True Range (ATR)
  • GKOS 3.27
  • ALKS 0.90
  • MACD
  • GKOS 0.56
  • ALKS -0.03
  • Stochastic Oscillator
  • GKOS 82.87
  • ALKS 37.97

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About ALKS Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Share on Social Networks: